VivoSeq
Other

Periodontal Disease

0

Pipeline Programs

9

Active Trials

1

Companies Involved

Periodontal Disease is an early-stage landscape with 0 programs across 1 company. The most active players are Eli Lilly.

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

27/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

20

clinical trials

Completed10 · 50%
Recruiting5 · 25%
Not yet recruiting4 · 20%
Unknown status1 · 5%

Trial Activity

20 trials

Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)